Neurodevelopment of Children Following Prenatal Exposure to Venlafaxine, Selective Serotonin Reuptake Inhibitors, or Untreated Maternal Depression
An examination of children of depressed mothers at age 3–6 found that IQs are lower in these children than in children of nondepressed mothers, and behavioral problems are somewhat more common. However, neither difference was related to prenatal antidepressant dose or duration. The child’s IQ is inf...
Gespeichert in:
Veröffentlicht in: | The American journal of psychiatry 2012-11, Vol.169 (11), p.1165-1174 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1174 |
---|---|
container_issue | 11 |
container_start_page | 1165 |
container_title | The American journal of psychiatry |
container_volume | 169 |
creator | Nulman, Irena Koren, Gideon Rovet, Joanne Barrera, Maru Pulver, Ariel Streiner, David Feldman, Brian |
description | An examination of children of depressed mothers at age 3–6 found that IQs are lower in these children than in children of nondepressed mothers, and behavioral problems are somewhat more common. However, neither difference was related to prenatal antidepressant dose or duration. The child’s IQ is influenced by the mother’s IQ and child’s sex. Behavioral problems are associated with the severity of the mother’s depression not only during gestation but also during early childhood.
ObjectiveEffects on child neurodevelopment of neurotransmitter reuptake inhibitors used as antidepressants during pregnancy have not been adequately studied. The authors compared the effects of prenatal exposure to venlafaxine (serotonin-norepinephrine reuptake inhibitor), selective serotonin reuptake inhibitors (SSRIs), and maternal depression.MethodA cohort derived from a prospectively collected database included four groups of children born to 1) depressed women who took venlafaxine during pregnancy (N=62), 2) depressed women who took SSRIs during pregnancy (N=62), 3) depressed women who were untreated during pregnancy (N=54), and 4) nondepressed, healthy women (N=62). The children’s intelligence and behavior outcomes were evaluated with standardized instruments at one time point between the ages of 3 years and 6 years, 11 months.ResultsThe children exposed to venlafaxine, SSRIs, and maternal depression during pregnancy had similar full-scale IQs (105, 105, and 108, respectively). The IQs of the venlafaxine and SSRI groups were significantly lower than that of the children of nondepressed mothers (112). The three groups exposed to maternal depression had consistently, but nonsignificantly, higher rates of most problematic behaviors than the children of nondepressed mothers. Severity of maternal depression in pregnancy and at testing predicted child behavior. Maternal IQ and child sex predicted child IQ. Antidepressant dose and duration during pregnancy did not predict any cognitive or behavioral outcome.ConclusionsFactors other than antidepressant exposure during pregnancy strongly predict children’s intellect and behavior. Depression during pregnancy is a significant risk factor for postpartum depression. Children of depressed mothers may be at risk of future psychopathology. |
doi_str_mv | 10.1176/appi.ajp.2012.11111721 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1466093672</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2914564481</sourcerecordid><originalsourceid>FETCH-LOGICAL-a446t-cdf5e15c9eb61162e447d515569882c4f4a9254e01d99f2dba6ad8c1601d09623</originalsourceid><addsrcrecordid>eNqNkdFuFCEUhonR2G31FRoSY9KLzhYYYIZLs7bapFaj1ng3YWfOWFYWEJhaX8MnlnW3NvHCyAWcc_Kd_wA_QoeUzClt5IkOwcz1KswZoayUymoYfYBmVNSiahhrH6IZIYRVStSf99B-SquSkrphj9EeqylrFatn6OclTNEPcAPWhzW4jP2IF9fGDhEcPvPW-u_GfcHvSqqztvj0Nvg0RcDZ40_grB71rXFwjD-AhT6bGyhR9Nk74_B7mELWXwGfu2uzNNnHdIx9xFcuR9AZBvym7NEV3ZcQIqRkvHuCHo3aJni6Ow_Q1dnpx8Xr6uLtq_PFi4tKcy5z1Q-jACp6BUtJqWTAeTMIKoRUbct6PnKtmOBA6KDUyIallnpoeypLgSjJ6gN0tNUN0X-bIOVubVIP1moHfkod5VISVcvmP1DKqWBKEl7QZ3-hKz9tXliougxXXJK2UHJL9dGnFGHsQjRrHX90lHQbg7uNwV0xuNsY3N0ZXBoPd_LTcg3Dn7Y7RwvwfAfo1Gs7Ru16k-45Wf5HUFW4esv9HnR_x3-P_wWDScH7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1316094608</pqid></control><display><type>article</type><title>Neurodevelopment of Children Following Prenatal Exposure to Venlafaxine, Selective Serotonin Reuptake Inhibitors, or Untreated Maternal Depression</title><source>MEDLINE</source><source>American Psychiatric Publishing</source><source>EZB Electronic Journals Library</source><creator>Nulman, Irena ; Koren, Gideon ; Rovet, Joanne ; Barrera, Maru ; Pulver, Ariel ; Streiner, David ; Feldman, Brian</creator><creatorcontrib>Nulman, Irena ; Koren, Gideon ; Rovet, Joanne ; Barrera, Maru ; Pulver, Ariel ; Streiner, David ; Feldman, Brian</creatorcontrib><description>An examination of children of depressed mothers at age 3–6 found that IQs are lower in these children than in children of nondepressed mothers, and behavioral problems are somewhat more common. However, neither difference was related to prenatal antidepressant dose or duration. The child’s IQ is influenced by the mother’s IQ and child’s sex. Behavioral problems are associated with the severity of the mother’s depression not only during gestation but also during early childhood.
ObjectiveEffects on child neurodevelopment of neurotransmitter reuptake inhibitors used as antidepressants during pregnancy have not been adequately studied. The authors compared the effects of prenatal exposure to venlafaxine (serotonin-norepinephrine reuptake inhibitor), selective serotonin reuptake inhibitors (SSRIs), and maternal depression.MethodA cohort derived from a prospectively collected database included four groups of children born to 1) depressed women who took venlafaxine during pregnancy (N=62), 2) depressed women who took SSRIs during pregnancy (N=62), 3) depressed women who were untreated during pregnancy (N=54), and 4) nondepressed, healthy women (N=62). The children’s intelligence and behavior outcomes were evaluated with standardized instruments at one time point between the ages of 3 years and 6 years, 11 months.ResultsThe children exposed to venlafaxine, SSRIs, and maternal depression during pregnancy had similar full-scale IQs (105, 105, and 108, respectively). The IQs of the venlafaxine and SSRI groups were significantly lower than that of the children of nondepressed mothers (112). The three groups exposed to maternal depression had consistently, but nonsignificantly, higher rates of most problematic behaviors than the children of nondepressed mothers. Severity of maternal depression in pregnancy and at testing predicted child behavior. Maternal IQ and child sex predicted child IQ. Antidepressant dose and duration during pregnancy did not predict any cognitive or behavioral outcome.ConclusionsFactors other than antidepressant exposure during pregnancy strongly predict children’s intellect and behavior. Depression during pregnancy is a significant risk factor for postpartum depression. Children of depressed mothers may be at risk of future psychopathology.</description><identifier>ISSN: 0002-953X</identifier><identifier>EISSN: 1535-7228</identifier><identifier>DOI: 10.1176/appi.ajp.2012.11111721</identifier><identifier>PMID: 23128923</identifier><identifier>CODEN: AJPSAO</identifier><language>eng</language><publisher>Arlington, VA: American Psychiatric Association</publisher><subject>Abnormalities, Drug-Induced - diagnosis ; Abnormalities, Drug-Induced - physiopathology ; Adult ; Adult and adolescent clinical studies ; Antidepressants ; Antidepressive Agents, Second-Generation - adverse effects ; Antidepressive Agents, Second-Generation - therapeutic use ; Biological and medical sciences ; Case-Control Studies ; Child Behavior Disorders - chemically induced ; Child Behavior Disorders - physiopathology ; Child, Preschool ; Cyclohexanols - adverse effects ; Cyclohexanols - therapeutic use ; Depression ; Depressive Disorder - drug therapy ; Depressive Disorder - physiopathology ; Dose-Response Relationship, Drug ; Female ; Humans ; Infant ; Infant, Newborn ; Intelligence ; Intelligence - drug effects ; Intelligence - physiology ; Longitudinal Studies ; Male ; Medical sciences ; Mental depression ; Mood disorders ; Neonatal Abstinence Syndrome - diagnosis ; Neonatal Abstinence Syndrome - physiopathology ; Neuropharmacology ; Neuropsychology ; Pharmacology. Drug treatments ; Pregnancy ; Pregnancy Complications - drug therapy ; Pregnancy Complications - physiopathology ; Prenatal development ; Prenatal exposure ; Prenatal Exposure Delayed Effects ; Prospective Studies ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Reference Values ; Retrospective Studies ; Serotonin Uptake Inhibitors - adverse effects ; Serotonin Uptake Inhibitors - therapeutic use ; Sex Factors ; Venlafaxine Hydrochloride ; Wechsler Scales</subject><ispartof>The American journal of psychiatry, 2012-11, Vol.169 (11), p.1165-1174</ispartof><rights>Copyright © 2012 by the American Psychiatric Association 2012</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2012 by the American Psychiatric Association</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a446t-cdf5e15c9eb61162e447d515569882c4f4a9254e01d99f2dba6ad8c1601d09623</citedby><cites>FETCH-LOGICAL-a446t-cdf5e15c9eb61162e447d515569882c4f4a9254e01d99f2dba6ad8c1601d09623</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://psychiatryonline.org/doi/epdf/10.1176/appi.ajp.2012.11111721$$EPDF$$P50$$Gappi$$H</linktopdf><linktohtml>$$Uhttps://psychiatryonline.org/doi/full/10.1176/appi.ajp.2012.11111721$$EHTML$$P50$$Gappi$$H</linktohtml><link.rule.ids>314,776,780,2842,21607,21608,21609,27903,27904,77540,77545</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26569519$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23128923$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nulman, Irena</creatorcontrib><creatorcontrib>Koren, Gideon</creatorcontrib><creatorcontrib>Rovet, Joanne</creatorcontrib><creatorcontrib>Barrera, Maru</creatorcontrib><creatorcontrib>Pulver, Ariel</creatorcontrib><creatorcontrib>Streiner, David</creatorcontrib><creatorcontrib>Feldman, Brian</creatorcontrib><title>Neurodevelopment of Children Following Prenatal Exposure to Venlafaxine, Selective Serotonin Reuptake Inhibitors, or Untreated Maternal Depression</title><title>The American journal of psychiatry</title><addtitle>Am J Psychiatry</addtitle><description>An examination of children of depressed mothers at age 3–6 found that IQs are lower in these children than in children of nondepressed mothers, and behavioral problems are somewhat more common. However, neither difference was related to prenatal antidepressant dose or duration. The child’s IQ is influenced by the mother’s IQ and child’s sex. Behavioral problems are associated with the severity of the mother’s depression not only during gestation but also during early childhood.
ObjectiveEffects on child neurodevelopment of neurotransmitter reuptake inhibitors used as antidepressants during pregnancy have not been adequately studied. The authors compared the effects of prenatal exposure to venlafaxine (serotonin-norepinephrine reuptake inhibitor), selective serotonin reuptake inhibitors (SSRIs), and maternal depression.MethodA cohort derived from a prospectively collected database included four groups of children born to 1) depressed women who took venlafaxine during pregnancy (N=62), 2) depressed women who took SSRIs during pregnancy (N=62), 3) depressed women who were untreated during pregnancy (N=54), and 4) nondepressed, healthy women (N=62). The children’s intelligence and behavior outcomes were evaluated with standardized instruments at one time point between the ages of 3 years and 6 years, 11 months.ResultsThe children exposed to venlafaxine, SSRIs, and maternal depression during pregnancy had similar full-scale IQs (105, 105, and 108, respectively). The IQs of the venlafaxine and SSRI groups were significantly lower than that of the children of nondepressed mothers (112). The three groups exposed to maternal depression had consistently, but nonsignificantly, higher rates of most problematic behaviors than the children of nondepressed mothers. Severity of maternal depression in pregnancy and at testing predicted child behavior. Maternal IQ and child sex predicted child IQ. Antidepressant dose and duration during pregnancy did not predict any cognitive or behavioral outcome.ConclusionsFactors other than antidepressant exposure during pregnancy strongly predict children’s intellect and behavior. Depression during pregnancy is a significant risk factor for postpartum depression. Children of depressed mothers may be at risk of future psychopathology.</description><subject>Abnormalities, Drug-Induced - diagnosis</subject><subject>Abnormalities, Drug-Induced - physiopathology</subject><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Antidepressants</subject><subject>Antidepressive Agents, Second-Generation - adverse effects</subject><subject>Antidepressive Agents, Second-Generation - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>Child Behavior Disorders - chemically induced</subject><subject>Child Behavior Disorders - physiopathology</subject><subject>Child, Preschool</subject><subject>Cyclohexanols - adverse effects</subject><subject>Cyclohexanols - therapeutic use</subject><subject>Depression</subject><subject>Depressive Disorder - drug therapy</subject><subject>Depressive Disorder - physiopathology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Intelligence</subject><subject>Intelligence - drug effects</subject><subject>Intelligence - physiology</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mental depression</subject><subject>Mood disorders</subject><subject>Neonatal Abstinence Syndrome - diagnosis</subject><subject>Neonatal Abstinence Syndrome - physiopathology</subject><subject>Neuropharmacology</subject><subject>Neuropsychology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pregnancy</subject><subject>Pregnancy Complications - drug therapy</subject><subject>Pregnancy Complications - physiopathology</subject><subject>Prenatal development</subject><subject>Prenatal exposure</subject><subject>Prenatal Exposure Delayed Effects</subject><subject>Prospective Studies</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Reference Values</subject><subject>Retrospective Studies</subject><subject>Serotonin Uptake Inhibitors - adverse effects</subject><subject>Serotonin Uptake Inhibitors - therapeutic use</subject><subject>Sex Factors</subject><subject>Venlafaxine Hydrochloride</subject><subject>Wechsler Scales</subject><issn>0002-953X</issn><issn>1535-7228</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkdFuFCEUhonR2G31FRoSY9KLzhYYYIZLs7bapFaj1ng3YWfOWFYWEJhaX8MnlnW3NvHCyAWcc_Kd_wA_QoeUzClt5IkOwcz1KswZoayUymoYfYBmVNSiahhrH6IZIYRVStSf99B-SquSkrphj9EeqylrFatn6OclTNEPcAPWhzW4jP2IF9fGDhEcPvPW-u_GfcHvSqqztvj0Nvg0RcDZ40_grB71rXFwjD-AhT6bGyhR9Nk74_B7mELWXwGfu2uzNNnHdIx9xFcuR9AZBvym7NEV3ZcQIqRkvHuCHo3aJni6Ow_Q1dnpx8Xr6uLtq_PFi4tKcy5z1Q-jACp6BUtJqWTAeTMIKoRUbct6PnKtmOBA6KDUyIallnpoeypLgSjJ6gN0tNUN0X-bIOVubVIP1moHfkod5VISVcvmP1DKqWBKEl7QZ3-hKz9tXliougxXXJK2UHJL9dGnFGHsQjRrHX90lHQbg7uNwV0xuNsY3N0ZXBoPd_LTcg3Dn7Y7RwvwfAfo1Gs7Ru16k-45Wf5HUFW4esv9HnR_x3-P_wWDScH7</recordid><startdate>20121101</startdate><enddate>20121101</enddate><creator>Nulman, Irena</creator><creator>Koren, Gideon</creator><creator>Rovet, Joanne</creator><creator>Barrera, Maru</creator><creator>Pulver, Ariel</creator><creator>Streiner, David</creator><creator>Feldman, Brian</creator><general>American Psychiatric Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>ASE</scope><scope>FPQ</scope><scope>K6X</scope></search><sort><creationdate>20121101</creationdate><title>Neurodevelopment of Children Following Prenatal Exposure to Venlafaxine, Selective Serotonin Reuptake Inhibitors, or Untreated Maternal Depression</title><author>Nulman, Irena ; Koren, Gideon ; Rovet, Joanne ; Barrera, Maru ; Pulver, Ariel ; Streiner, David ; Feldman, Brian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a446t-cdf5e15c9eb61162e447d515569882c4f4a9254e01d99f2dba6ad8c1601d09623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Abnormalities, Drug-Induced - diagnosis</topic><topic>Abnormalities, Drug-Induced - physiopathology</topic><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Antidepressants</topic><topic>Antidepressive Agents, Second-Generation - adverse effects</topic><topic>Antidepressive Agents, Second-Generation - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>Child Behavior Disorders - chemically induced</topic><topic>Child Behavior Disorders - physiopathology</topic><topic>Child, Preschool</topic><topic>Cyclohexanols - adverse effects</topic><topic>Cyclohexanols - therapeutic use</topic><topic>Depression</topic><topic>Depressive Disorder - drug therapy</topic><topic>Depressive Disorder - physiopathology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Intelligence</topic><topic>Intelligence - drug effects</topic><topic>Intelligence - physiology</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mental depression</topic><topic>Mood disorders</topic><topic>Neonatal Abstinence Syndrome - diagnosis</topic><topic>Neonatal Abstinence Syndrome - physiopathology</topic><topic>Neuropharmacology</topic><topic>Neuropsychology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pregnancy</topic><topic>Pregnancy Complications - drug therapy</topic><topic>Pregnancy Complications - physiopathology</topic><topic>Prenatal development</topic><topic>Prenatal exposure</topic><topic>Prenatal Exposure Delayed Effects</topic><topic>Prospective Studies</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Reference Values</topic><topic>Retrospective Studies</topic><topic>Serotonin Uptake Inhibitors - adverse effects</topic><topic>Serotonin Uptake Inhibitors - therapeutic use</topic><topic>Sex Factors</topic><topic>Venlafaxine Hydrochloride</topic><topic>Wechsler Scales</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nulman, Irena</creatorcontrib><creatorcontrib>Koren, Gideon</creatorcontrib><creatorcontrib>Rovet, Joanne</creatorcontrib><creatorcontrib>Barrera, Maru</creatorcontrib><creatorcontrib>Pulver, Ariel</creatorcontrib><creatorcontrib>Streiner, David</creatorcontrib><creatorcontrib>Feldman, Brian</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>British Nursing Index</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>British Nursing Index</collection><jtitle>The American journal of psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nulman, Irena</au><au>Koren, Gideon</au><au>Rovet, Joanne</au><au>Barrera, Maru</au><au>Pulver, Ariel</au><au>Streiner, David</au><au>Feldman, Brian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neurodevelopment of Children Following Prenatal Exposure to Venlafaxine, Selective Serotonin Reuptake Inhibitors, or Untreated Maternal Depression</atitle><jtitle>The American journal of psychiatry</jtitle><addtitle>Am J Psychiatry</addtitle><date>2012-11-01</date><risdate>2012</risdate><volume>169</volume><issue>11</issue><spage>1165</spage><epage>1174</epage><pages>1165-1174</pages><issn>0002-953X</issn><eissn>1535-7228</eissn><coden>AJPSAO</coden><abstract>An examination of children of depressed mothers at age 3–6 found that IQs are lower in these children than in children of nondepressed mothers, and behavioral problems are somewhat more common. However, neither difference was related to prenatal antidepressant dose or duration. The child’s IQ is influenced by the mother’s IQ and child’s sex. Behavioral problems are associated with the severity of the mother’s depression not only during gestation but also during early childhood.
ObjectiveEffects on child neurodevelopment of neurotransmitter reuptake inhibitors used as antidepressants during pregnancy have not been adequately studied. The authors compared the effects of prenatal exposure to venlafaxine (serotonin-norepinephrine reuptake inhibitor), selective serotonin reuptake inhibitors (SSRIs), and maternal depression.MethodA cohort derived from a prospectively collected database included four groups of children born to 1) depressed women who took venlafaxine during pregnancy (N=62), 2) depressed women who took SSRIs during pregnancy (N=62), 3) depressed women who were untreated during pregnancy (N=54), and 4) nondepressed, healthy women (N=62). The children’s intelligence and behavior outcomes were evaluated with standardized instruments at one time point between the ages of 3 years and 6 years, 11 months.ResultsThe children exposed to venlafaxine, SSRIs, and maternal depression during pregnancy had similar full-scale IQs (105, 105, and 108, respectively). The IQs of the venlafaxine and SSRI groups were significantly lower than that of the children of nondepressed mothers (112). The three groups exposed to maternal depression had consistently, but nonsignificantly, higher rates of most problematic behaviors than the children of nondepressed mothers. Severity of maternal depression in pregnancy and at testing predicted child behavior. Maternal IQ and child sex predicted child IQ. Antidepressant dose and duration during pregnancy did not predict any cognitive or behavioral outcome.ConclusionsFactors other than antidepressant exposure during pregnancy strongly predict children’s intellect and behavior. Depression during pregnancy is a significant risk factor for postpartum depression. Children of depressed mothers may be at risk of future psychopathology.</abstract><cop>Arlington, VA</cop><pub>American Psychiatric Association</pub><pmid>23128923</pmid><doi>10.1176/appi.ajp.2012.11111721</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-953X |
ispartof | The American journal of psychiatry, 2012-11, Vol.169 (11), p.1165-1174 |
issn | 0002-953X 1535-7228 |
language | eng |
recordid | cdi_proquest_miscellaneous_1466093672 |
source | MEDLINE; American Psychiatric Publishing; EZB Electronic Journals Library |
subjects | Abnormalities, Drug-Induced - diagnosis Abnormalities, Drug-Induced - physiopathology Adult Adult and adolescent clinical studies Antidepressants Antidepressive Agents, Second-Generation - adverse effects Antidepressive Agents, Second-Generation - therapeutic use Biological and medical sciences Case-Control Studies Child Behavior Disorders - chemically induced Child Behavior Disorders - physiopathology Child, Preschool Cyclohexanols - adverse effects Cyclohexanols - therapeutic use Depression Depressive Disorder - drug therapy Depressive Disorder - physiopathology Dose-Response Relationship, Drug Female Humans Infant Infant, Newborn Intelligence Intelligence - drug effects Intelligence - physiology Longitudinal Studies Male Medical sciences Mental depression Mood disorders Neonatal Abstinence Syndrome - diagnosis Neonatal Abstinence Syndrome - physiopathology Neuropharmacology Neuropsychology Pharmacology. Drug treatments Pregnancy Pregnancy Complications - drug therapy Pregnancy Complications - physiopathology Prenatal development Prenatal exposure Prenatal Exposure Delayed Effects Prospective Studies Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Reference Values Retrospective Studies Serotonin Uptake Inhibitors - adverse effects Serotonin Uptake Inhibitors - therapeutic use Sex Factors Venlafaxine Hydrochloride Wechsler Scales |
title | Neurodevelopment of Children Following Prenatal Exposure to Venlafaxine, Selective Serotonin Reuptake Inhibitors, or Untreated Maternal Depression |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T21%3A35%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neurodevelopment%20of%20Children%20Following%20Prenatal%20Exposure%20to%20Venlafaxine,%20Selective%20Serotonin%20Reuptake%20Inhibitors,%20or%20Untreated%20Maternal%20Depression&rft.jtitle=The%20American%20journal%20of%20psychiatry&rft.au=Nulman,%20Irena&rft.date=2012-11-01&rft.volume=169&rft.issue=11&rft.spage=1165&rft.epage=1174&rft.pages=1165-1174&rft.issn=0002-953X&rft.eissn=1535-7228&rft.coden=AJPSAO&rft_id=info:doi/10.1176/appi.ajp.2012.11111721&rft_dat=%3Cproquest_cross%3E2914564481%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1316094608&rft_id=info:pmid/23128923&rfr_iscdi=true |